Trial
NCT07052682
A Study to Evaluate How Ontamalimab Works and Assess Its Safety and Tolerability in People With Nonalcoholic Steatohepatitis With Fibrosis Stages 1 to 4
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Takeda
Collaborators
—
Condition
Steatohepatitis
Intervention
Ontamalimab
Why stopped
Study was terminated early by the sponsor due to a strategic shift and reprioritization of clinical programs within Takeda.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-08-19